Skip to main content
Premium Trial:

Request an Annual Quote

Public Comment Phase on Warfarin Genetic Test Reimbursement Ends Tomorrow

NEW YORK (GenomeWeb News) – The Center for Medicare and Medicaid Services will stop taking public comments tomorrow, Sept. 3, about whether Medicare should provide reimbursement for DNA tests for the common anticoagulant warfarin.
Tomorrow marks the end of a public comment phase begun a month ago as part of a CMS National Coverage Analysis investigation to determine whether there is sufficient evidence that a pharmacogenomic test for warfarin is effective enough for coverage.
The US Food and Drug Administration updated the label for warfarin in 2007 to state that people with variations of the genes CYP2C9 and VKORC1 may respond to warfarin differently than patients without those variations.
FDA Deputy Commissioner Janet Woodcock said at the time that the administration was not directing doctors to use genetic tests, and that the agency intended it as “informational” to doctors about the variability of drug response.
Public comments about the CMS review are available here.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.